Atara Biotherapeutics

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.? With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.

网站

https://www.atarabio.com

Atara Biotherapeutics的外部链接

所属行业

生物技术研究

规模

201-500 人

总部

Thousand Oaks，CA

类型

上市公司

创立

2012

领域

biotechnology、immunotherapy、cell therapy、gene therapy、regenerative medicine、T-cells、cytotoxic T lymphocytes、CTLs、allogeneic、off the shelf、cancer、oncology、immuno-oncology、hematology、immunology、autoimmune diseases、multiple sclerosis、MS、Epstein-Barr virus、EBV、post-transplant lymphoproliferative disorder、PTLD、nasopharyngeal carcinoma、Cytomegalovirus、CMV、oncoviruses、bone marrow transplant、stem cell transplant、solid organ transplant、lymphoma、secondary lymphoma、secondary malignancy、lymphoproliferative disorders、EBV lymphoma、Atara Bio、Atara、ATRA、CAR T、solid tumors、Allogeneic CD19 CAR T、Allogeneic EBV CAR T-cell platform、Allogeneic CAR T-cell therapies和progressive multiple sclerosis